← All themes

Obesity drugs stocks

비만치료제

What are Obesity drugs stocks in Korea?

The Obesity drugs theme on jonbur groups 13 Korean stocks listed on KOSPI and KOSDAQ, worth ₩26T in total. On Oct 27, 2026 the group moved down 1.51% (weighted by market value); the largest members are Yuhan, Hanmi Pharm, SAM Chun Dang Pharm.

Key facts

Stocks
13
Total market value
₩26T
Day's move
−1.51%
As of
Oct 27, 2026
Largest members
Yuhan, Hanmi Pharm, SAM Chun Dang Pharm

Earnings tracker · 3Q 2026

Reporting season · reports due by Nov 14

3 of 13 reportedOperating profit up vs a year ago: 2 of 3
Revenue+1.9%
Operating profit+3.2%
Net profitTurned to profit

Combined, for the companies that have reported, vs the same quarter a year ago

CompanyReportedRevenuevs a year agoOperating profitvs a year agovs last quarterOp. margin
YuhanOct 28Preliminary₩586B+2.8%₩35B+57.8%−48.0%5.9%3.9%
Hanmi PharmOct 27Preliminary₩377B+4.2%₩38B−31.3%−71.2%10.0%15.2%
Dong-A STOct 27Preliminary₩207B−4.4%₩21B+52.9%+239.9%10.4%6.5%
Hanmi ScienceExpected around Oct 29
HK inno.NExpected around Oct 29
IL Dong PharmaceuticalExpected around Nov 6
Daewoong PharmaExpected around Nov 7
G2GBIOExpected around Nov 13
SAM Chun Dang PharmExpected around Nov 14
PeptronExpected around Nov 14
D&D PharmatechExpected around Nov 14
RaphasExpected around Nov 14
Inventage LabExpected around Dec 1

Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.

Technical breadth

After the close on Oct 27, 2026
Above 20-day average
25%
Above 60-day average
25%
RSI above 70
0%
RSI below 30
16.7%
52-week highs
0
52-week lows
2

Index gauge · Short term

Bearish

0 bullish, 1 neutral, 8 bearish

Index gauge · Medium term

Bearish

0 bullish, 1 neutral, 7 bearish

Technical read

Across the 12 Obesity drugs theme members, only 25% sit above their 20-day and 60-day averages, indicating weak breadth on both horizons. None of the members is at a 52-week high, while 2 are at 52-week lows, and the lowest member RSI reads 16.7 with no member showing an RSI near overbought levels. The equal-weighted theme index is labeled bearish on both short and medium horizons, with an RSI of 40.3 and price sitting below its cloud.

Written by AI from the indicator values above. Not advice.

Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.

Credit & macro

No notable credit, ELS or macro events for these companies in the last 30 days.

Obesity drugs

−1.40%

비만치료제

The obesity drugs theme covers Korean companies involved in developing, manufacturing, or contract-producing medications for weight management, including GLP-1-based injectables and related peptide therapies. Korean investors group these firms together because many of them supply active ingredients, formulation technology, or contract manufacturing for global pharmaceutical developers, and because the category has drawn attention from the broader global shift toward incretin-based treatments. The theme is often discussed alongside diabetes treatments, since many obesity drugs share mechanisms and development pathways with them.

13 companies · 4 up · 0 flat · 9 down

Traded value
₩150B
Value vs 20-day average
0.73×
Top gainer
Dong-A ST
+2.95%
Largest company
Yuhan
₩5.9T

Companies in this theme

CompanyPriceDailyTraded valueMarket capNPS
Yuhan000100 · KOSPI
₩80,000−2.08%₩16B₩5.9T6.83%
Hanmi Pharm128940 · KOSPI
₩350,500−0.57%₩26B₩4.5T9.61%
Hanmi Science008930 · KOSPI
₩41,400−2.01%₩5B₩2.8T6.27%
Daewoong Pharma069620 · KOSPI
₩99,100−1.49%₩2.2B₩1.1T10.30%
IL Dong Pharmaceutical249420 · KOSPI
₩12,650+2.02%₩915M₩400B2.30%
Dong-A ST170900 · KOSPI
₩34,900+2.95%₩1.2B₩340B4.78%

Source: KRX statistical information